Jonathan P Feelemyer1, Don C Des Jarlais2, Kamyar Arasteh3, Benjamin W Phillips4, Holly Hagan5. 1. The Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, New York City, USA. Electronic address: jfeelemyer@chpnet.org. 2. The Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, New York City, USA. Electronic address: ddesjarlais@chpnet.org. 3. The Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, New York City, USA. Electronic address: karasteh@chpnet.org. 4. The Baron Edmond de Rothschild Chemical Dependency Institute, Beth Israel Medical Center, New York City, USA. Electronic address: benjiwphillips@gmail.com. 5. NYU College of Nursing, New York University, New York City, USA. Electronic address: hh50@nyu.edu.
Abstract
BACKGROUND: Opioid substitution treatment (OST) can increase quality of life (WHOQOL-BREF) and reduce addiction severity index (ASI) scores among participants over time. OST program participants have noted that improvement in quality of life is one of the most important variables to their reduction in drug use. However, there is little systematic understanding of WHOQOL-BREF and ASI domain changes among OST participants in low and middle-income countries (LMIC). METHODS: Utilizing PRISMA guidelines we conducted a systematic literature search to identify OST program studies documenting changes in WHOQOL-BREF or ASI domains for participants in buprenorphine or methadone programs in LMIC. Standardized mean differences for baseline and follow-up domain scores were compared along with relationships between domain scores, OST dosage, and length of follow-up. RESULTS: There were 13 OST program studies with 1801 participants from five countries eligible for inclusion in the review. Overall, statistically significant changes were noted in all four WHOQOL-BREF domain and four of the seven ASI domain scores (drug, psychological, legal, and family) documented in studies. Dosage of pharmacologic medication and length of follow-up did not affect changes in domain scores. CONCLUSION: WHOQOL-BREF and ASI domain scoring is a useful tool in measuring overall quality of life and levels of addiction among OST participants. Coupled with measurements of blood-borne infection, drug use, relapse, and overdose, WHOQOL-BREF and ASI represent equally important tools for evaluating the effects of OST over time and should be further developed as integrated tools in the evaluation of participants in LMIC.
BACKGROUND: Opioid substitution treatment (OST) can increase quality of life (WHOQOL-BREF) and reduce addiction severity index (ASI) scores among participants over time. OST program participants have noted that improvement in quality of life is one of the most important variables to their reduction in drug use. However, there is little systematic understanding of WHOQOL-BREF and ASI domain changes among OST participants in low and middle-income countries (LMIC). METHODS: Utilizing PRISMA guidelines we conducted a systematic literature search to identify OST program studies documenting changes in WHOQOL-BREF or ASI domains for participants in buprenorphine or methadone programs in LMIC. Standardized mean differences for baseline and follow-up domain scores were compared along with relationships between domain scores, OST dosage, and length of follow-up. RESULTS: There were 13 OST program studies with 1801 participants from five countries eligible for inclusion in the review. Overall, statistically significant changes were noted in all four WHOQOL-BREF domain and four of the seven ASI domain scores (drug, psychological, legal, and family) documented in studies. Dosage of pharmacologic medication and length of follow-up did not affect changes in domain scores. CONCLUSION:WHOQOL-BREF and ASI domain scoring is a useful tool in measuring overall quality of life and levels of addiction among OST participants. Coupled with measurements of blood-borne infection, drug use, relapse, and overdose, WHOQOL-BREF and ASI represent equally important tools for evaluating the effects of OST over time and should be further developed as integrated tools in the evaluation of participants in LMIC.
Keywords:
Addiction severity index; Low and middle income countries; Opioid dependence; Opioid substitution treatment (OST); People who inject drugs; Quality of life (WHOQOL-BREF)
Authors: Bach Xuan Tran; Arto Ohinmaa; Anh Thuy Duong; Nhan Thi Do; Long Thanh Nguyen; Quoc Cuong Nguyen; Steve Mills; Philip Jacobs; Stan Houston Journal: Qual Life Res Date: 2011-07-06 Impact factor: 4.147
Authors: P Todd Korthuis; Mary Jo Tozzi; Vijay Nandi; David A Fiellin; Linda Weiss; James E Egan; Michael Botsko; Angela Acosta; Marc N Gourevitch; David Hersh; Jeffrey Hsu; Joshua Boverman; Frederick L Altice Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: S S Solomon; C S Hawcroft; P Narasimhan; R Subbaraman; A K Srikrishnan; A J Cecelia; M Suresh Kumar; Suniti Solomon; J E Gallant; D D Celentano Journal: Indian J Med Res Date: 2008-05 Impact factor: 2.375
Authors: John Strang; Nora D Volkow; Louisa Degenhardt; Matthew Hickman; Kimberly Johnson; George F Koob; Brandon D L Marshall; Mark Tyndall; Sharon L Walsh Journal: Nat Rev Dis Primers Date: 2020-01-09 Impact factor: 52.329
Authors: Omary Ubuguyu; Olivia C Tran; Robert Douglas Bruce; Frank Masao; Cassian Nyandindi; Norman Sabuni; Sheryl McCurdy; Jessie Mbwambo; Barrot H Lambdin Journal: Int J Drug Policy Date: 2016-03-11
Authors: Ann E Kurth; Charles M Cleland; Don C Des Jarlais; Helgar Musyoki; John A Lizcano; Nok Chhun; Peter Cherutich Journal: J Acquir Immune Defic Syndr Date: 2015-12-01 Impact factor: 3.731
Authors: Louisa Degenhardt; Jason Grebely; Jack Stone; Matthew Hickman; Peter Vickerman; Brandon D L Marshall; Julie Bruneau; Frederick L Altice; Graeme Henderson; Afarin Rahimi-Movaghar; Sarah Larney Journal: Lancet Date: 2019-10-23 Impact factor: 79.321